Express News | Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
10-Q: Quarterly report
Express News | Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success Through Patient Affordability
Express News | Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (Hpv), Advancing Tvgn 920
Express News | Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI Into Preclinical Processes, Accelerating Drug Development and Reducing Costs